FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 661 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by... May 1, 2024 Lack of Immunity Against SARS-CoV-2 in a Large Tertiary Care Centre... September 2, 2020 Pastor Opens Homeless Shelter And Moves In To Raise Money For... December 29, 2021 Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for... August 27, 2025 Load more HOT NEWS What to Know About Biomarker Testing for Lung Cancer: An Expert... For HPV-Positive Women, Test Can Guide Cervical Cancer Screening Follow-Up Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab... What Latino People Should Know About Quitting Smoking and Health Disparities:...
